Citi analyst Yigal Nochomovitz lowered his price target on ArriVent BioPharma (NASDAQ: AVBP) to $40 from $43, while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE